RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

GILEAD SCIENCES, INC.

GILD

Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0000882095

SHARE:XLINKEDINEMAIL
Revenue FY2025
$29.44B
Net Income
$8.51B
EPS (Basic)
$6.84
Net Margin
28.9%
ROE
37.5%
Total Equity
$22.70B
Shares Out
1.24B

GILEAD SCIENCES, INC. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 12 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
Holocene Advisors
Holocene Advisors
$0.41B
0.8%
+23.2%
Dodge & Cox
Dodge & Cox
$2.99B
0.6%
(2.4%)
Capital World Investors
Capital World Investors
$5.18B
0.6%
(0.7%)
Motley Fool Asset Management
Motley Fool Asset Management
$0.01B
0.5%
(4.4%)
Capital Research Global Investors
Capital Research Global Investors
$2.45B
0.3%
(28.5%)
Renaissance Technologies
Renaissance Technologies
$0.28B
0.3%
+3.0%
Ariel Investments
John Rogers
$0.02B
0.2%
(3.3%)
Adage Capital Management
Adage Capital Management
$0.14B
0.2%
+17.0%
Royce & Associates
Royce & Associates
$0.00B
0.0%
—
Bridgewater Associates
Bridgewater Associates
$0.04B
0.0%
+60.9%
Alps Advisors
Alps Advisors
$0.01B
0.0%
+34.6%
Mairs & Power
Mairs & Power
$0.00B
0.0%
—

Insider Transactions

Reading stored insider transactions…